Folgueira et al. identified HtrA1 as one of a cohort of only 3 genes (HtrA1, MTSS1, CLPTM1) that could distinguish doxorubicin-responsive from non-responsive breast cancers in 95% of samples [19]. The gene discussed is HTRA1; the disease is breast carcinoma.